{"url_path":"/sec/mdcx/8-k/2026-09-11/item-3-02","section_key":"item-3-02","section_title":"Item 3.02 Unregistered Sales of Equity Securities.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-09-11","source_url":"https://www.sec.gov/Archives/edgar/data/1997296/0001062993-26-004898-index.html","accession_number":"0001062993-26-004898","cik":"0001997296","ticker":"MDCX","issuer_name":"Medicus Pharma Ltd.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1997296/0001062993-26-004898-index.html","primary_entity_key":"0001997296","primary_entity_name":"Medicus Pharma Ltd."},"word_count":186,"has_tables":true,"body_markdown":"**Item 3.02 Unregistered Sales of Equity Securities.**\n\nOn September 4, 2026, Medicus Pharma Ltd. (the \"Company\") awarded cash bonuses in the aggregate amount of approximately $1.45 million to certain officers and employees of the Company. Each of the recipients elected to forgo payment of his or her cash bonus and instead receive the value of such bonus in restricted common shares of the Company (the \"Common Shares\").\n\nIn accordance with these elections, the Company granted an aggregate of 8,529,412 restricted Common Shares to such officers and employees. The number of restricted common shares issued to each recipient was determined by dividing the amount of the cash bonus such recipient elected to forgo by $0.1705 per share, being the closing price of the Common Shares on the Nasdaq Capital Market on September 3, 2026. No additional consideration was paid to, or received by, the Company in connection with the issuance.\n\nThe issuance of the restricted Common Shares was exempt from the registration requirements of the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof as a transaction by an issuer not involving a public offering."}